Mode of action

Tavlesse has a unique targeted mechanism of action to reduce platelet destruction1

Tavlesse is the first and only treatment that targets spleen tyrosine kinase (SYK) in macrophages to inhibit downstream signalling and platelet destruction in chronic ITP1-4

Want to know more about Tavlesse?
Sign up to our mailing list

Watch how Tavlesse inhibits downstream signalling which prevents platelet destruction in chronic ITP

*The active metabolite of TAVLESSE is R406.

ITP: immune thrombocytopenia

References:

  1. Bussel J, Arnold DM, Grossbard E, et al. Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: results of two phase 3, randomized, placebo-controlled trials. Am J Hematol. 2018;93(7):921-930.
  2. Newland A, Lee E, McDonald V, et al. Fostamatinib for persistent/chronic adult immune thrombocytopenia. Immunotherapy. 2018;10(1):9-25.
  3. Tavlesse Summary of Product Characteristics. Great Britain. Grifols. Date of revision: January 2021. Available at https://www.medicines.org.uk/emc/product/11479 . Accessed on 14/2/2022.
  4. Tavlesse Summary of Product Characteristics. Northern Ireland. Grifols. Date of revision: August 2021. Available at https://www.emcmedicines.com/en-gb/northernireland/medicine?id=9c2f7cf0-129d-42a3-a61c-d729ae80e50c. Accessed on 14/2/2022.
  5. Shih A, Nazi I, Kelton JG, et al. Novel treatments for immune thrombocytopenia. Presse Med. 2014;43:e87-e95.
  6. Nimmerjahn F, Ravetch J. Fc receptors as regulators of immune responses. Nature. 2008;8:34-47.